Brentuximab Vedotin로 치료한 CD30 양성 대세포 이행을 보인 균상식육종 1예
CD30+ Large-Cell Transformation of Mycosis Fungoides Treated with Brentuximab Vedotin
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCIScopus
- 저널 순위
- Scopus Q4KCI Q3
- 저널
- 대한피부과학회지60(2) · pp.106 · 2022
- 피인용
- Scopus 0KCI 0
- FWCI (Scopus)
- 0
- ISSN
- 0494-4739
저자
- 신준오제1저자Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
- 배경남Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
- 손진화Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
- 신기혁Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
- 김훈수Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
- 고현창Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
- 김문범Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
- 김병수교신저자Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
초록
Large-cell transformation of mycosis fungoides (LCT-MF) is an advanced stage of primary cutaneous T-cell lymphoma with a poor prognosis. Therapeutic options for these patients are often limited, and so far, they are not promising. An 81-year-old woman with a previous history of mycosis fungoides presented with aggravation of generalized erythematous scaly patches and new onset of ulcerated tumor on the abdomen for 3 months. Histopathological examination revealed a dense dermal infiltrate composed of atypical large lymphocytes. Immunohistochemically, the tumor cells were positive for CD30 expression. A diagnosis of CD30+ LCT-MF was established. She was intensively treated with methotrexate (1 month), acitretin (1 month), and rituximab with dose-modified cyclophosphamide, doxorubicin, and prednisone (1 cycle). Despite such treatments, the improvement was minimal. Subsequently, the patient was started on brentuximab vedotin, 1.8 mg/kg intravenously once every 3 weeks. She responded well to brentuximab therapy, and the skin lesions completely subsided within 12 weeks of treatment
키워드
식별자
- Scopus EID
- 2-s2.0-85137278967
- KCI
- ART002814589



로그인
연구물 목록으로